Wu JM; Wei DY, Luo YF, Xiang XY (November 2003). “[Clinic research on heroin de-addiction effects of acupuncture and its potentiality of preventing relapse]”. Zhong Xi Yi Jie He Xue Bao1 (4): 268–72. doi:10.3736/jcim20030412. PMID15339529.
Lejeune C; Floch-Tudal C, Montamat S, Crenn-Hebert C, Simonpoli AM (March 1997). “[Management of drug addict pregnant women and their children]”. Arch Pediatr4 (3): 263–70. doi:10.1016/S0929-693X(97)87247-8. PMID9181022.
Bokhan NA; Abolonin AF, Krylov EN, Vetlugina TP, Ivanova SA (2003). “Comparative Efficiency of Proproten-100 during the Therapy of Patients with Alcoholism in the Stage of Therapeutic Remission”. Bull Exp Biol Med135 (Suppl 1): 171–5. doi:10.1023/A:1024709014483. PMID12949690.
Voltaire-Carlsson A; Hiltunen AJ, Koechling UM, Borg S (Sep–Oct 1996). “Effects of long-term abstinence on psychological functioning: a prospective longitudinal analysis comparing alcohol-dependent patients and healthy volunteers”. Alcohol13 (5): 415–21. doi:10.1016/0741-8329(96)81678-8. PMID8888936.
Watanabe KI; Ogihara-Hashizume A, Kobayashi Y, Mitsushio H, Komiyama T (April 2001). “Impaired sleep during the post-alcohol withdrawal period in alcoholic patients”. Addict Biol6 (2): 163–169. doi:10.1080/13556210020040244. PMID11341856.
Vik PW; Cellucci T, Jarchow A, Hedt J (March 2004). “Cognitive impairment in substance abuse”. Psychiatr Clin North Am27 (1): 97–109. doi:10.1016/S0193-953X(03)00110-2. PMID15062633.
Janiri L; Martinotti G, Dario T, Reina D, Paparello F, Pozzi G, Addolorato G, Di Giannantonio M, De Risio S (June 3, 2005). “Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study”. Neuropsychobiology52 (1): 37–44. doi:10.1159/000086176. PMID15942262.
Curran, Hv; Bond, A; O'Sullivan, G; Bruce, M; Marks, I; Lelliot, P; Shine, P; Lader, M (November 1994). “Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder.”. Psychological Medicine24 (4): 969–76. doi:10.1017/S0033291700029056. ISSN0033-2917. PMID7892364.
Rimondini R; Sommer WH, Dall'Olio R, Heilig M (March 2008). “Long-lasting tolerance to alcohol following a history of dependence”. Addict Biol13 (1): 26–30. doi:10.1111/j.1369-1600.2007.00079.x. PMID17850416.
Ahveninen J; Jääskeläinen IP, Pekkonen E, Hallberg A, Hietanen M, Näätänen R, Sillanaukee P (June 8, 1999). “Post-withdrawal changes in middle-latency auditory evoked potentials in abstinent human alcoholics”. Neurosci Lett268 (2): 57–60. doi:10.1016/S0304-3940(99)00378-X. PMID10400077.
Kiefer F; Andersohn F, Jahn H, Wolf K, Raedler TJ, Wiedemann K (January 2002). “Involvement of plasma atrial natriuretic peptide in protracted alcohol withdrawal”. Acta Psychiatr Scand105 (1): 65–70. doi:10.1034/j.1600-0447.2002.0_011.x. PMID12086228.
Bruijnzeel AW; Gold MS (November 2005). “The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence”. Brain Res Brain Res Rev49 (3): 505–28. doi:10.1016/j.brainresrev.2005.01.007. PMID16269317.
Wilde MI; Wagstaff AJ (June 1997). “Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification”. Drugs53 (6): 1038–53. doi:10.2165/00003495-199753060-00008. PMID9179530.
Malcolm R; Myrick H, Brady KT, Ballenger JC (2001). “Update on anticonvulsants for the treatment of alcohol withdrawal”. Am J Addict10 Suppl: 16–23. doi:10.1080/10550490150504100. PMID11268817.
Le Bon O; Murphy JR, Staner L, Hoffmann G, Kormoss N, Kentos M, Dupont P, Lion K, Pelc I, Verbanck P (August 2003). “Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations”. J Clin Psychopharmacol23 (4): 377–83. doi:10.1097/01.jcp.0000085411.08426.d3. PMID12920414.
Mueller TI; Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA, Recupero PR (February 1997). “A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence”. Alcohol Clin Exp Res21 (1): 86–92. doi:10.1111/j.1530-0277.1997.tb03733.x. PMID9046378.
Wu JM; Wei DY, Luo YF, Xiang XY (November 2003). “[Clinic research on heroin de-addiction effects of acupuncture and its potentiality of preventing relapse]”. Zhong Xi Yi Jie He Xue Bao1 (4): 268–72. doi:10.3736/jcim20030412. PMID15339529.
Lejeune C; Floch-Tudal C, Montamat S, Crenn-Hebert C, Simonpoli AM (March 1997). “[Management of drug addict pregnant women and their children]”. Arch Pediatr4 (3): 263–70. doi:10.1016/S0929-693X(97)87247-8. PMID9181022.
Stojek A; Madejski J, Dedelis E, Janicki K (May–Jun 1990). “[Correction of the symptoms of late substance withdrawal syndrome by intra-conjunctival administration of 5% homatropine solution (preliminary report)]”. Psychiatr Pol24 (3): 195–201. PMID2084727.
Bokhan NA; Abolonin AF, Krylov EN, Vetlugina TP, Ivanova SA (2003). “Comparative Efficiency of Proproten-100 during the Therapy of Patients with Alcoholism in the Stage of Therapeutic Remission”. Bull Exp Biol Med135 (Suppl 1): 171–5. doi:10.1023/A:1024709014483. PMID12949690.
Voltaire-Carlsson A; Hiltunen AJ, Koechling UM, Borg S (Sep–Oct 1996). “Effects of long-term abstinence on psychological functioning: a prospective longitudinal analysis comparing alcohol-dependent patients and healthy volunteers”. Alcohol13 (5): 415–21. doi:10.1016/0741-8329(96)81678-8. PMID8888936.
Watanabe KI; Ogihara-Hashizume A, Kobayashi Y, Mitsushio H, Komiyama T (April 2001). “Impaired sleep during the post-alcohol withdrawal period in alcoholic patients”. Addict Biol6 (2): 163–169. doi:10.1080/13556210020040244. PMID11341856.
Vik PW; Cellucci T, Jarchow A, Hedt J (March 2004). “Cognitive impairment in substance abuse”. Psychiatr Clin North Am27 (1): 97–109. doi:10.1016/S0193-953X(03)00110-2. PMID15062633.
Janiri L; Martinotti G, Dario T, Reina D, Paparello F, Pozzi G, Addolorato G, Di Giannantonio M, De Risio S (June 3, 2005). “Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study”. Neuropsychobiology52 (1): 37–44. doi:10.1159/000086176. PMID15942262.
Curran, Hv; Bond, A; O'Sullivan, G; Bruce, M; Marks, I; Lelliot, P; Shine, P; Lader, M (November 1994). “Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder.”. Psychological Medicine24 (4): 969–76. doi:10.1017/S0033291700029056. ISSN0033-2917. PMID7892364.
Rimondini R; Sommer WH, Dall'Olio R, Heilig M (March 2008). “Long-lasting tolerance to alcohol following a history of dependence”. Addict Biol13 (1): 26–30. doi:10.1111/j.1369-1600.2007.00079.x. PMID17850416.
Ahveninen J; Jääskeläinen IP, Pekkonen E, Hallberg A, Hietanen M, Näätänen R, Sillanaukee P (June 8, 1999). “Post-withdrawal changes in middle-latency auditory evoked potentials in abstinent human alcoholics”. Neurosci Lett268 (2): 57–60. doi:10.1016/S0304-3940(99)00378-X. PMID10400077.
Kiefer F; Andersohn F, Jahn H, Wolf K, Raedler TJ, Wiedemann K (January 2002). “Involvement of plasma atrial natriuretic peptide in protracted alcohol withdrawal”. Acta Psychiatr Scand105 (1): 65–70. doi:10.1034/j.1600-0447.2002.0_011.x. PMID12086228.
Bruijnzeel AW; Gold MS (November 2005). “The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence”. Brain Res Brain Res Rev49 (3): 505–28. doi:10.1016/j.brainresrev.2005.01.007. PMID16269317.
Beleslin D (1991). “[Modern drug therapy in alcoholism]”. Med Pregl44 (7-8): 279–84. PMID1806768.
Wilde MI; Wagstaff AJ (June 1997). “Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification”. Drugs53 (6): 1038–53. doi:10.2165/00003495-199753060-00008. PMID9179530.
Malcolm R; Myrick H, Brady KT, Ballenger JC (2001). “Update on anticonvulsants for the treatment of alcohol withdrawal”. Am J Addict10 Suppl: 16–23. doi:10.1080/10550490150504100. PMID11268817.
Le Bon O; Murphy JR, Staner L, Hoffmann G, Kormoss N, Kentos M, Dupont P, Lion K, Pelc I, Verbanck P (August 2003). “Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations”. J Clin Psychopharmacol23 (4): 377–83. doi:10.1097/01.jcp.0000085411.08426.d3. PMID12920414.
Mueller TI; Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA, Recupero PR (February 1997). “A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence”. Alcohol Clin Exp Res21 (1): 86–92. doi:10.1111/j.1530-0277.1997.tb03733.x. PMID9046378.
Hori T; Komiyama T, Harada S, Matsumoto T (2005). “[Treatment of substance dependence by a bio-cognitive model based on behavioral pharmacology]”. Seishin Shinkeigaku Zasshi107 (11): 1147–58. PMID16408423.